Macclesfield, United Kingdom

Gary Fairley


 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gary Fairley: Innovator in Pharmaceutical Chemistry

Introduction

Gary Fairley is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on pyridine and pyrazine derivatives. His research has implications for the treatment of cell proliferative disorders, showcasing his commitment to advancing medical science.

Latest Patents

Gary Fairley holds a patent for pyridine and pyrazine derivatives, specifically identified as -083. This invention concerns the development of these derivatives, or their pharmaceutically-acceptable salts, which are defined by specific formulas. The patent outlines processes for their preparation, pharmaceutical compositions containing them, and their use in manufacturing medicaments aimed at treating various cell proliferative disorders. This patent highlights his expertise and dedication to improving therapeutic options.

Career Highlights

Fairley is associated with AstraZeneca AB, a leading global biopharmaceutical company. His role at AstraZeneca has allowed him to work on cutting-edge research and development projects that aim to address critical health challenges. His contributions to the company reflect his commitment to innovation in the pharmaceutical industry.

Collaborations

Throughout his career, Gary Fairley has collaborated with esteemed colleagues, including Bernard Christophe Barlaam and Craig Steven Harris. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical solutions.

Conclusion

In summary, Gary Fairley is a distinguished inventor whose work on pyridine and pyrazine derivatives has the potential to impact the treatment of cell proliferative disorders significantly. His association with AstraZeneca and collaborations with other professionals further underscore his contributions to the field of pharmaceutical chemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…